“Ionotropic Glutamate Receptor Antagonists - Pipeline Insight, 2022” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Ionotropic Glutamate Receptor Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Ionotropic Glutamate Receptor Antagonists: Overview Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system (CNS) and exerts its biological activity through a variety of receptors. Glutamate receptors (GluRs) are divided into two major classes on the basis of the mechanism by which they relay their signal: the ionotropic glutamate receptors (iGluRs), which are ligand-gated cation channels, and the metabotropic glutamate receptors (mGluRs) that are G protein-coupled receptors. It is widely accepted that glutamate-mediated neuronal hyperexcitation plays a causative role in eliciting seizures. Among glutamate receptors, the roles of N-methyl-D-aspartate (NMDA) and ?-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors in physiological and pathological conditions represent major clinical research targets. NMDA or AMPA receptor antagonists have been shown to inhibit seizures in animal models, suggesting a potential role for NMDA and AMPA receptor antagonists in anti-seizure drug development.
"Ionotropic Glutamate Receptor Antagonists - Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ionotropic Glutamate Receptor Antagonists pipeline landscape is provided which includes the disease overview and Ionotropic Glutamate Receptor Antagonists treatment guidelines. The assessment part of the report embraces, in depth Ionotropic Glutamate Receptor Antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ionotropic Glutamate Receptor Antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights • The companies and academics are working to assess challenges and seek opportunities that could influence Ionotropic Glutamate Receptor Antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Ionotropic Glutamate Receptor Antagonists.
Ionotropic Glutamate Receptor Antagonists Emerging Drugs Chapters This segment of the Ionotropic Glutamate Receptor Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Ionotropic Glutamate Receptor Antagonists Emerging Drugs • AXS-05: Axsome Therapeutics
AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for the treatment of central nervous system (CNS) conditions. AXS-05 consists of a proprietary formulation and dose of dextromethorphan (DM) and bupropion. The dextromethorphan component of AXS-05 is an antagonist of the NMDA receptor, an ionotropic glutamate receptor, and a sigma-1 receptor agonist. The bupropion component of AXS-05 serves primarily to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor. In April 2021, Axsome Therapeutics announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s New Drug Application (NDA) for AXS-05 for the treatment of major depressive disorder (MDD), and has granted the application Priority Review.
• REL-1017: Relmada Therapeutics
REL-1017, an NCE and novel NMDAR channel blocker with a preference for hyperactive channels associated with major depressive disorder (MDD), has entered its Phase III registration program as an adjunctive treatment for MDD. Data from the Phase II trial with REL-1017 suggest rapid onset and sustained antidepressant effects with statistically significant improvements as compared to placebo on efficacy measures. Safety and tolerability results in the Phase II study were also consistent with those reported in previously reported Phase I studies. The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for REL-1017 as an adjunctive treatment of MDD.
Further product details are provided in the report……..
Ionotropic Glutamate Receptor Antagonists: Therapeutic Assessment This segment of the report provides insights about the different Ionotropic Glutamate Receptor Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Ionotropic Glutamate Receptor Antagonists
There are approx. 30+ key companies which are developing the therapies for Ionotropic Glutamate Receptor Antagonists. The companies which have their Ionotropic Glutamate Receptor Antagonists drug candidates in the most advanced stage, i.e. Pre-registration include, Axsome Therapeutics.
This report covers around 30+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Ionotropic Glutamate Receptor Antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Ionotropic Glutamate Receptor Antagonists: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ionotropic Glutamate Receptor Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ionotropic Glutamate Receptor Antagonists drugs.
Current Treatment Scenario and Emerging Therapies: • How many companies are developing Ionotropic Glutamate Receptor Antagonists drugs?
• How many Ionotropic Glutamate Receptor Antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ionotropic Glutamate Receptor Antagonists?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ionotropic Glutamate Receptor Antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ionotropic Glutamate Receptor Antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?
Global Narcolepsy Therapeutics Market to Reach $4,912.3 Million by 2032 Global Narcolepsy Therapeutics Market: Industry Overview The global narcolepsy therapeutics market is projected to reach $4,912.3 million by 2032 from $915.2 million in 2021 at a CAGR of 15.93% during the forecast period...
“Electroencephelographs (EEG)–Pipeline Insight and 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline devices in Electroencephelographs pipeline landscape. Increased incidence of disorders like Alzheimer’s disease, epilepsy, Dementia, Multiple Sclerosis, Parkinson’s disease, and stroke around the world has been...
Leber Congenital Amaurosis (LCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Leber Congenital Amaurosis (LCA) – Drugs In Development, 2022, provides an overview of the Leber Congenital...
Resistant Pseudomonas aeruginosa Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary This latest Pharmaceutical and Healthcare disease pipeline guide Resistant Pseudomonas aeruginosa Infections – Drugs In Development, 2022, provides an overview...
242 pages •
By The Business Research Company
• Jun 2022
Coronavirus (COVID-19) Current Therapy Global Market Opportunities And Strategies To 2030: COVID-19 Growth And Change provides the strategists; marketers and senior management with the critical information they need to assess the global coronavirus (COVID-19) current therapy market as it emerges from the COVID 19 shut down. Description: Where...
Metabotropic Glutamate Receptor 7 (GPRC1G or MGLUR7 or GRM7) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Summary According to the recently published report ’Metabotropic Glutamate Receptor 7 - Drugs In Development, 2022’; Metabotropic...
Scientific advancements in nucleic acid-based therapies have significantly impacted the global biopharmaceutical industry. The ribonucleic acid (RNA) therapeutics market is expected to witness remarkable clinical progress as therapies target “undruggable” pathways. Technologically advanced platforms are integrated into RNA therapeutics...
120 pages •
By Infiniti Research Limited
• May 2022
Global Neurologic Disorders Therapeutics Market 2022-2026 The analyst has been monitoring the neurologic disorders therapeutics market and it is poised to grow by $ 33.46 bn during 2022-2026, accelerating at a CAGR of 5.44% during the forecast period. Our report on the neurologic disorders therapeutics market provides a...
155 pages •
By Future Market Insight Global & Consulting Pvt Ltd
• Apr 2022
A recent market study published on the animal model market offers a U.S. industry analysis for 2017-2021 and an opportunity assessment for 2022-2032. The report consists of a comprehensive assessment of the most important market dynamics. On conducting thorough research on the historical as well as current growth parameters of the animal model...
The global asthma therapeutics market size reached US$ 17.9 Billion in 2021. Looking forward, the analyst expects the market to reach US$ 20.1 Billion by 2027, exhibiting a growth rate (CAGR) of 2.13% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.